Nina Nouhravesh, Caroline Sindet-Pedersen, Maja Hellfritzsch, Ali Akil Al-Alak, Thomas Kümler, Erik L Grove, Morten Lamberts
INTRODUCTION: Pharmacokinetic drug-drug interactions (DDIs) are challenging aspects of direct oral anticoagulant (DOAC) therapy in patients with cancer. We evaluated the prevalence of potential DOAC/antineoplastic agent DDIs and the one-year cumulative incidence of switching from low-molecular-weight heparin (LMWH) to a DOAC in patients with cancer. METHODS: Patients with cancer and an indication of LMWH were included from Herlev and Gentofte Hospital, Denmark, in the 2014-2019 period...
January 25, 2024: Danish Medical Journal